8:02 am Merrimack Pharma announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment.
View todays social media effects on MACK
View the latest stocks trending across Twitter. Click to view dashboard